Protara Therapeutics, Inc. (TARA)
2.53
+0.09
(+3.69%)
USD |
NASDAQ |
Nov 13, 16:00
2.525
0.00 (0.00%)
After-Hours: 19:59
Protara Therapeutics Enterprise Value : 27.10M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 27.10M |
| November 12, 2026 | 21.71M |
| November 11, 2026 | 32.50M |
| November 10, 2026 | 21.11M |
| November 09, 2026 | 25.90M |
| November 06, 2026 | 13.31M |
| November 05, 2026 | 3.117M |
| November 04, 2026 | 16.31M |
| November 03, 2026 | 19.91M |
| November 02, 2026 | 19.91M |
| October 30, 2026 | 24.11M |
| October 29, 2026 | 26.50M |
| October 28, 2026 | 24.71M |
| October 27, 2026 | 23.51M |
| October 26, 2026 | 16.31M |
| October 23, 2026 | 15.11M |
| October 22, 2026 | 21.71M |
| October 21, 2026 | 25.31M |
| October 20, 2026 | 28.90M |
| October 19, 2026 | 15.11M |
| October 16, 2026 | 14.51M |
| October 15, 2026 | 19.31M |
| October 14, 2026 | 24.11M |
| October 13, 2026 | 32.50M |
| October 12, 2026 | 41.50M |
| Date | Value |
|---|---|
| October 09, 2026 | 40.60M |
| October 08, 2026 | 34.30M |
| October 07, 2026 | 30.70M |
| October 06, 2026 | 28.60M |
| October 05, 2026 | 33.10M |
| October 02, 2026 | 37.30M |
| October 01, 2026 | 40.90M |
| September 30, 2026 | 58.29M |
| September 29, 2026 | 49.91M |
| September 28, 2026 | 52.28M |
| September 25, 2026 | 54.05M |
| September 24, 2026 | 58.19M |
| September 23, 2026 | 69.41M |
| September 22, 2026 | 77.68M |
| September 21, 2026 | 67.64M |
| September 18, 2026 | 70.00M |
| September 17, 2026 | 78.87M |
| September 16, 2026 | 74.14M |
| September 15, 2026 | 81.82M |
| September 14, 2026 | 91.27M |
| September 11, 2026 | 85.96M |
| September 10, 2026 | 84.18M |
| September 09, 2026 | 86.55M |
| September 08, 2026 | 90.09M |
| September 04, 2026 | 93.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.108M |
| Brainstorm Cell Therapeutics, Inc. | 12.28M |
| Summit Therapeutics, Inc. | 10.71B |
| Kezar Life Sciences, Inc. | -11.12M |
| Clene, Inc. | 68.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.69M |
| Total Expenses (Quarterly) | 21.69M |
| EPS Diluted (Quarterly) | -0.3451 |
| Earnings Yield | -54.75% |
| Normalized Earnings Yield | -54.75 |